Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Decaffeinated Coffee Might Boost Brain Power for Type 2 Diabetes

Decaf coffee was found to improve glucose energy metabolism in the brain in mouse studies....

Advertisement

Type 2 diabetes is linked to cognitive decline, dementia and Alzheimer's disease that stems from impaired breakdown of glucose needed for optimal brain function. The study is the first to show decaffeinated coffee might prevent and treat declining memory associated with Type 2 diabetes, aging and neurodegenerative disorders.

For the study researchers gave mice induced to develop diabetes a decaf coffee supplement for five months and then evaluated the mouse brain's genetic response to the treatment. The result was increased ability of the brain to metabolize glucose.

Giulio Maria Pasinetti, MD, PhD, Professor of Neurology, and Psychiatry, at Mount Sinai School of Medicine, said it's important to find ways to prevent cognitive decline from neurodegenerative diseases. Studies show pathological changes in the brain occur decades before Alzheimer's and other diseases develop. He also notes the study shows not all of the health benefits associated with coffee come from caffeine.

It's important to note that coffee can have negative cardiovascular effects and is linked to elevated blood pressure and cholesterol levels, making consumption risky for some.

Pasinetti plans to explore whether decaffeinated coffee could be useful as a dietary supplement in humans to prevent or even treat memory loss associated with Type 2 diabetes and other brain disorders.

Nutritional Neuroscience H. Lap et al.Nov. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2012 and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology



Search Articles On Diabetes In Control